Vivesto — M&A Activity 2013

Jan 7, 2013

News Details

Ad-hoc | 7 January 2013 13:00

Oasmia Pharmaceutical AB: Oasmia Pharmaceutical AB and Abbott Sign Global Collaboration Agreement for Canine Oncology Therapies

Oasmia Pharmaceutical AB / Key word(s): Alliance

07.01.2013 13:00

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

2013-01-07

Oasmia Pharmaceutical AB and Abbott Sign Global Collaboration Agreement for
Canine Oncology Therapies

UPPSALA, Sweden
Oasmia and Abbott have entered into an exclusive global collaboration
agreement with respect to Oasmia's two leading animal health product
candidates, Paccal(R) Vet and Doxophos(R) Vet. The agreement significantly
expands the nature and scope of the initial collaboration that was
initially entered into in 2009 between Oasmia and Abbott regarding these
products.

Under the terms of the expanded agreement, Abbott Animal Health will obtain
exclusive license and distribution rights to the products for essentially
the entire world. In return, Oasmia will receive an upfront payment and is
eligible to receive additional milestone payments of up to $21.5M subject
to Oasmia meeting various product development and sales milestones. In
addition, in the event either or both of the products are commercialized,
Oasmia shall receive tiered royalties on net sales. Oasmia will continue
to fund research, development and manufacture of Paccal(R) Vet and
Doxophos(R) Vet.

• I am very pleased that we have reached this expanded agreement between
  our companies. We will now have one world-class partner for essentially the
  entire global canine oncology market. In addition to the well-established
  markets in the industrialized countries, we believe that there is great
  future market potential in developing countries as medical innovation
  allows dedicated owners to treat emerging health issues in their beloved
  companion animals, said Julian Aleksov, chief executive officer, Oasmia
  Pharmaceutical.

The agreement does not include the rights to Paccal(R) Vet in Russia, Japan
and the Commonwealth of Independent States (CIS), or the rights to
Doxophos(R) Vet in Russia and the CIS.

Cancer is the leading cause of canine disease-related deaths, with up to 3
million new cases diagnosed annually worldwide. Cancer accounts for nearly
50 percent of all deaths in dogs 10 years of age or older. Cancer is seen
more often in some breeds, notably the Golden Retriever, Boxer, Greyhounds
and Bernese Mountain dogs. While environmental factors play a role, the
incidence of cancer seen in breeds such as these suggests a certain genetic
predisposition to certain types of cancers. Researchers are studying both
canine and human genomes to unlock the genetics of cancer.

About Paccal(R) Vet
Paccal(R) Vet is a novel nanoparticle formulation composed of Oasmia
Pharmaceutical's patented excipient XR-17 and the anti-cancer substance
paclitaxel. XR-17 can be used to improve the solubility of substances, such
as paclitaxel, one of the most frequently used chemotherapeutic substances
in the world. Many drugs based on paclitaxel are dissolved in lipid soluble
formulations, which are associated with a range of side-effects. These can
usually be controlled in humans with pre-medication, but the reaction can
be fatal in dogs despite pre-medication. Paccal(R) Vet data for a market
authorization are under review by the United States Food and Drug
Administration.

About Doxophos(R) Vet
The active substance in Doxophos(R) Vet is doxorubicin, one of the most
used cytotoxic substances in the world. Permanent damage to the heart may
occur due to exposure to doxorubicin through intravenous administration. In
Doxophos(R) Vet, doxorubicin forms an insoluble salt with the novel
excipient XR-17. When reconstituted in a suitable aqueous solvent, the salt
forms nanoparticle-sized micelles. Doxophos(R) Vet is designed to reduce
the risk of heart damage allowing for a higher dose to be given.
Doxophos(R) Vet has been granted Minor Use Minor Species designation by the
United States Food and Drug Administration and is currently in clinical
development.

About Oasmia Pharmaceutical AB
(NASDAQ OMX: OASM) (General Standard of Frankfurt Stock Exchange: OMAX,
ISIN SE0000722365) Oasmia Pharmaceutical AB develops new generations of
drugs within human and veterinary oncology. The Company's product
development aims to create and manufacture novel nanoparticle formulations
and drug-delivery systems based on well-established cytostatics which, in
comparison with current alternatives, show improved properties, reduced
side-effects, and expanded applications. The Company's product development
is based on its proprietary in-house research and company patents. The
Company's common stock is listed on NASDAQ OMX Stockholm and the Frankfurt
Stock Exchange.

About Abbott Animal Health
Abbott Animal Health is dedicated to providing a better future for animals,
pet owners and veterinary professionals. Abbott's continuing education
programs, comprehensive training tools, on-call expertise and technical
service set the standard in the industry. Abbott products are trusted at
thousands of veterinary hospitals and clinics every day.

About Abbott
Abbott is a global healthcare company devoted to improving life through the
development of products and technologies that span the breadth of
healthcare. With a portfolio of leading, science-based offerings in
diagnostics, medical devices, nutritionals and branded generic
pharmaceuticals, Abbott serves people in more than 150 countries and
employs approximately 70,000 people.

Oasmia Pharmaceutical AB Forward Looking Statements
This announcement contains forward-looking statements. These statements are
based on expectations in light of the information that is currently
available, as well as assumptions that are subject to risks and
uncertainties that could cause actual results to differ materially from
such statements. These risks and uncertainties include, but are not limited
to, domestic and international economic conditions, industry and market
conditions, and changes of interest rate and currency exchange rate, in
general, and completion and discontinuation of clinical trials, obtaining
regulatory approvals, claims and concerns about product safety and
efficacy, technological advances, domestic and foreign healthcare reforms,
and changes of laws and regulations, in particular, with respect to each of
Paccal(R) Vet and Doxophos(R) Vet. The company disclaims any intention or
obligation to update or revise any forward-looking statements whether as a
result of new information, future events or otherwise. This announcement
contains information on pharmaceuticals (including pharmaceuticals under
development) but is not intended to, and does not, make any
representations, warranties or claims regarding the efficacy or
effectiveness of these pharmaceuticals or provide medical advice of any
kind.

For more information, please contact: Johan Edin, acting Head of Public
Relations, Oasmia Pharmaceutical AB. E-mail: press@oasmia.com Phone: +46
(0) 18 50 54 40. German contact: Dr. Sönke Knop, Peggy Kropmanns, edicto
GmbH, Frankfurt E-Mail: oasmia@edicto.de Phone: +49 (0) 69 90 55 05 51.
Information is also available at www.oasmia.com www.nasdaqomxnordic.com
www.boerse-frankfurt.de twitter.com/oasmia

'Oasmia is required under the Financial Instruments Trading Act to make the
information in this press release public. The information was submitted for
publication at 13.00 on January 7, 2013.'

07.01.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---